INOVIO PHARMACEUTICALS INC (INO) Stock Price, Quote, News and Overview
NASDAQ:INO - Nasdaq - US45773H4092 - Common Stock
INO Quote and Key Statistics
INOVIO PHARMACEUTICALS INC
NASDAQ:INO (1/21/2025, 8:07:44 PM)
Premarket: 2.18 -0.02 (-0.91%)2.2
+0.12 (+5.77%)
INO Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.43% | ||
| ROE | -153.49% | ||
| Debt/Equity | 0 |
INO Performance and Technical Analysis
INO Ownership and Analysts
INO Latest News and Analysis
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
What's Going On With Inovio Pharmaceuticals (INO) Stock?
Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses.
Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing
Inovio Pharmaceuticals shares are trading higher by 20.7% Tuesday afternoon. Vaccine stocks are rising amid growing concerns about respiratory illnesses.
INOVIO Announces Pricing of $30 Million Public Offering
/PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
INOVIO Announces Proposed Public Offering
/PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
INOVIO Reports Inducement Grant Under Inducement Plan
/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
About INO
Company Profile
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 122 full-time employees. The firm is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
Company Info
INOVIO PHARMACEUTICALS INC
6769 Mesa Ridge Rd.
San Diego CALIFORNIA 19462 US
CEO: J. Joseph Kim
Employees: 127
Company Website: https://www.inovio.com/
Investor Relations: https://ir.inovio.com
Phone: 18584103134
INO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |